Shares of Enovis Co. (NYSE:ENOV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $71.44.
A number of brokerages recently weighed in on ENOV. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Enovis in a report on Friday, May 3rd. Evercore ISI dropped their price objective on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. began coverage on Enovis in a report on Thursday, June 13th. They set a “neutral” rating and a $53.00 price objective on the stock.
Check Out Our Latest Stock Report on Enovis
Institutional Trading of Enovis
Enovis Stock Down 1.9 %
Shares of NYSE ENOV opened at $45.80 on Thursday. The company has a market cap of $2.51 billion, a P/E ratio of -30.53 and a beta of 1.92. The firm has a 50-day simple moving average of $46.98 and a two-hundred day simple moving average of $54.59. Enovis has a 1 year low of $43.04 and a 1 year high of $65.88. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.10 and a quick ratio of 1.03.
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.50. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The company had revenue of $516.00 million during the quarter, compared to analysts’ expectations of $505.62 million. During the same quarter in the previous year, the business earned $0.44 EPS. Enovis’s revenue was up 27.0% compared to the same quarter last year. Research analysts anticipate that Enovis will post 2.62 earnings per share for the current year.
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Read More
- Five stocks we like better than Enovis
- Investing in Travel Stocks Benefits
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- What Does Downgrade Mean in Investing?
- Has This Leading Tech Stock Halted the AI Surge?
- Following Congress Stock Trades
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.